Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...
Adenocarcinoma grows in the tissue of the prostate gland, but other types of cancer can also start in the prostate or spread ...
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...
The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma ...
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
4d
Pharmaceutical Technology on MSNFDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerThe US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
A research team led by Prof. JIANG Yanyi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, ...
Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...
The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results